Multiple Myeloma clinical trials

The registry lists 3,627 studies for Multiple Myeloma across more than 10 countries. 741 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.

Studies

Recruiting first, then most recently updated. Showing 50 of 3,627 — search for more.

• Restrictive Versus Standard Antibiotic Treatment During CAR-T TherapyNot yet recruitingNCT07842198Phase 21 country
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Phase 324 countries
• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 15 countries
• Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART StudyRecruitingNCT06052826Phase 21 country
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Phase 325 countries
• A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Phase 48 countries
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Phase 211 countries
• Study on the Clinical Efficacy of Teclistamab and TalquetamabRecruitingNCT064777831 country
• A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT0516058412 countries
• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 11 country
• A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingNCT06500884Phase 27 countries
• A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT07336472Phase 1/21 country
• A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingNCT07665450Phase 34 countries
• A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingNCT07149857Phase 23 countries
• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)RecruitingNCT07393282Phase 34 countries
• A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)RecruitingNCT07073547Phase 11 country
• Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)RecruitingNCT07609940Phase 41 country
• A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Phase 318 countries
• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Phase 315 countries
• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 11 country
• Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingNCT06948084Phase 21 country
• A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Phase 15 countries
• Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentRecruitingNCT067841671 country
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 21 country
• A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07116616Phase 1/21 country
• Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F InjectionNot yet recruitingNCT078330461 country
• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruitingNCT026826671 country
• Long-term Follow-up of Patients Treated With Genetically Modified Autologous T CellsEnrolling by invitationNCT03628612Phase 23 countries
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 22 countries
• 18F-Fluciclovine PET/CT in Multiple MyelomaRecruitingNCT06103838Phase 21 country
• Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaRecruitingNCT06465316Phase 11 country
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 21 country
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07095452Phase 2/34 countries
• Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 11 country
• Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple MyelomaRecruitingNCT06474182Not applicable1 country
• CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 21 country
• Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple MyelomaRecruitingNCT03909412Phase 11 country
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 21 country
• ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingNCT06997081Phase 21 country
• Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingNCT07648264Phase 311 countries
• F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07828522Phase 2
• Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsRecruitingNCT07210047Phase 1/21 country
• A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"RecruitingNCT07382739Phase 21 country
• CBC-Based Inflammatory Indices in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07823959
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04910568Phase 113 countries
• Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT04879043Phase 1/25 countries
• A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Phase 31 country
• CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingNCT07585760Phase 21 country
• A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple MyelomaRecruitingNCT07760454Phase 1/21 country
• Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingNCT07825064Phase 21 country